Our results have demonstrated that tailored chemotherapy based on ERCC1, RRM1, and β-tubulin III expression showed significantly increased response rate, median PFS time, and 1-year survival rate in patients with NSCLC, without an increase in adverse effects. This evidence concerns the gene RRM1 and non-small cell lung carcinoma.